Claroid Pharma Files IPO Draft Papers To Offer 1.26 Crore Shares: Here Are The Key Risk Factors
A ipo & listings development with market-wide reach.
23 Sept 2026 · NDTV Profit
The company plans to utilise the net proceeds from the fresh issue towards funding capital expenditure for setting up a new pharmaceutical manufacturing facility on its existing land.
The analysis
Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
Market context
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Jio IPO likely by Oct end at enterprise valuation of above ₹12 trillion
Jio IPO GMP latest price today: Grey market premium is rising day by day - Check expected price band
Wizz Financial bets on India with cross-border fintech push, eyes 2029 IPO
Reliance Jio IPO: Rs 37,700 crore mega issue, full schedule & 5 must-know details
Kanohar Electricals soars 20%; stock up 79% from IPO price in three weeks